메지온

140410KOSDAQ

41.0 / 100

Reference Date: 2026-10-23

Financial Score15.5 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 20.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Meizon is a pharmaceutical company established in 2002, focusing on global new drug development for various diseases, including erectile dysfunction and single-ventricle syndrome treatments. Although it submitted a New Drug Application (NDA) to the FDA for a single-ventricle syndrome treatment in 2021, the application was temporarily withdrawn following a request for additional clinical trials, and the company is now proceeding with the additional trial process.

Number of Employees

18people

Average Salary

63.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-110.44Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

7.31Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼40.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼8.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -58.6% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 57,500Won52-week high 172,70052-week low 51,000

1-month return0.0Point

1m -20.25% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-20
Neutral주식등의대량보유상황보고서(일반)2026-10-08
Neutral주식등의대량보유상황보고서(일반)2026-10-02